Multivariable linear regression models evaluating the association between NAFLD Fibrosis Score risk categories and continuous cardiometabolic risk factors.

<p>Multivariable linear regression models evaluating the association between NAFLD Fibrosis Score risk categories and continuous cardiometabolic risk factors.</p

Prediction of the risk for liver fibrosis among participants with NAFLD (n = 575) according to the AST/ALT ratio, APRI, FIB4, and NFS.

<p>For the AST/ALT ratio, significant risk of fibrosis was defined as an AST/ALT ratio > 1.0 and absence of significant fibrosis as an AST/ALT ratio ≤ 1.0. *We also show the predicted risk of fibrosis for the AST/ALT ratio using the 0.8 cut-off. For the APRI, a significant risk/intermediate risk of fibrosis was defined as an APRI > 0.5 while an absence of fibrosis was defined as APRI ≤ 0.5. For the FIB4, we defined significant fibrosis as a FIB4 > 2.67 and a low risk of fibrosis as FIB4 < 1.30 with values in-between defined as indeterminate. For the NFS, we used the following definitions for the risk categories: high risk advanced fibrosis (NFS > 0.676), indeterminate risk for advanced fibrosis (1.455 ≤ NFS ≤ 0.676), and low risk for advanced fibrosis (NFS < -1.455).</p

Baseline characteristics of the study sample, by presence or absence of NAFLD.

<p>Baseline characteristics of the study sample, by presence or absence of NAFLD.</p

Characteristics of participants with fatty liver according to risk of fibrosis as predicted by the NAFLD Fibrosis Score.

<p>Characteristics of participants with fatty liver according to risk of fibrosis as predicted by the NAFLD Fibrosis Score.</p

Results of top SNPs (p-value <1.25E-7) from GWAS of Alzheimer disease, fibrinogen, HDL and uric acid using 550K genotype data and incorporated genotype data.

<p>Results of top SNPs (p-value <1.25E-7) from GWAS of Alzheimer disease, fibrinogen, HDL and uric acid using 550K genotype data and incorporated genotype data.</p

Mean imputation certainty of the top SNPs in the entire 3121 imputed sample and in the person-specific certainty >0.5, SNP-specific certainty >0.6 and phenotyped sample.

†<p><b><i>N</i></b>: the number of phenotyped and imputed individuals with person-specific certainty >0.5 and SNP-specific certainty >0.6.</p

Scatter plots of –log₁₀(p-value) from 550K GWAS and GWAS using incorporated genotype data.

<p>Scatter plots of –log₁₀(p-value) from 550K GWAS and GWAS using incorporated genotype data.</p

Sample characteristics of Alzheimer disease, fibrinogen, HDL and uric acid data in the genotyped and imputed sample.

<p>For continuous variables, mean value and standard deviation (in parenthesis) are presented, while for binary variables, the number of cases and its proportion (in parenthesis) are presented.</p

Top SNPs (p-value <1.25E-7) from GWAS of Alzheimer disease, fibrinogen, HDL and uric acid using 550K genotype data.

†<p>Position in base pairs, based on NCBI build 36.1 (hg18).</p>*<p>MAF is computed in genotyped and phenotyped sample.</p>††<p>rs4420638 is a marker of the APOE haplotype.</p

Number of genome-wide significant SNPs (p-value <1.25E-7) with improved statistical significance (smaller p-value) from GWAS of Alzheimer disease, fibrinogen, HDL and uric acid using incorporated genotype data (new GWAS).

<p>Number of genome-wide significant SNPs (p-value <1.25E-7) with improved statistical significance (smaller p-value) from GWAS of Alzheimer disease, fibrinogen, HDL and uric acid using incorporated genotype data (new GWAS).</p